Medivation (MDVN) is an oncology focused biotechnology company. Its only drug is an androgen receptor blocker called Xtandi, approved for treating metastatic castrate resistant prostate cancer (mCRPC) patients that have failed chemotherapy (post-chemo). The agent is undergoing Phase III development as treatment for mCRPC patients that have not received chemotherapy (pre-chemo). In addition, the compound is being evaluated in a Phase I study as treatment for breast cancer.
Xtandi's market launch in September 2012 followed that of Zytiga in May 2011. Both drugs treat post-chemo mCRPC patients. Moreover, both affect testosterone signaling, but through different mechanisms of action. Xtandi inhibits androgen receptor (AR) activity at three steps: it prevents the binding of...
Only subscribers can access this article, which is part of the PRO research library covering 3,609 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: